Alnylam Pharmaceuticals, Inc. ALNY R3KPHARMA
Company Overview
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Generates a return on equity of 96.6%, reflecting efficient use of shareholder capital.
Revenue has grown at a 35.6% CAGR over the past five years.
Maintains a net profit margin of 16.1%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.71B (+65.2% YoY); net profit $313.75M.
- Trailing 12 Months Year-on-year growth — revenue +66.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 35.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.59% |
| 1 Year: | 66.90% |
Stock Price Performance
| 1 Year: | -39.86% |
| 6 Months: | -19.62% |
| 3 Months: | -10.97% |
| 1 Month: | +18.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.86 · Neutral
P/E of 45.23 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 96.6%.
- Compounding revenue at 35.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 47.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALNY Alnylam Pharmaceuticals, Inc. R3KPHARMA | 260.10 | 45.23 | $34.80B | 0.00% | 14.33% | 96.56% | 35.59% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 18.96M | 15.93M | 17.10M | 37.92M | 21.90M | 29.91M | 2.07M | 21.03M | 33.29M | 44.71M | 70.06M | 71.68M | 99.48M | 103.96M | 125.85M | 163.56M | 177.57M | 220.55M | - | 213.26M | 224.82M | 264.31M | 319.29M | 318.75M | 750.53M | 494.33M | 659.83M | 500.92M | 594.19M | 773.69M | 1.25B | - | 1.29B |
| Operating Income | -72.94M | -78.33M | - | -110.03M | -92.45M | -106.68M | - | -106.51M | -120.47M | -125.80M | - | -147.41M | -192.35M | -254.56M | - | -188.79M | -236.27M | -216.30M | - | -210.16M | -198.86M | -225.20M | - | -186.25M | -146.16M | -181.68M | -146.73M | -191.69M | -258.04M | -149.81M | -229.83M | 213.87M | -43.44M | 48.61M | -76.91M | 18.08M | -16.20M | 367.98M | - | 231.44M |
| Net Income | -71.78M | -76.79M | -90.72M | -102.97M | -90.13M | -104.07M | -112.93M | -107.29M | -118.42M | -122.94M | -142.23M | -141.21M | -163.56M | -245.28M | -211.44M | -181.91M | -219.48M | -208.53M | -276.19M | -182.22M | -179.23M | -253.29M | -243.54M | -200.29M | -189.56M | -204.51M | -240.34M | -277.40M | -405.92M | -174.10M | -276.02M | 147.75M | -65.94M | -16.89M | -111.57M | -18.25M | -72.23M | 251.08M | 205.99M | 164.49M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.56 | -2.18 | - | -1.71 | -1.61 | -1.72 | -2.00 | -2.29 | -3.32 | -1.40 | -2.21 | 1.15 | -0.52 | -0.13 | -0.87 | -0.14 | -0.55 | 1.84 | - | 1.21 |
| R&D Expense | 67.01M | 68.62M | - | 96.27M | 83.17M | 97.94M | - | 86.98M | 90.63M | 95.25M | - | 96.86M | 137.58M | 139.94M | - | 129.13M | 163.89M | 160.80M | - | 169.57M | 155.00M | 161.78M | - | 185.90M | 182.63M | 194.57M | 169.89M | 205.71M | 245.37M | 230.57M | 248.53M | 253.18M | 261.00M | 294.14M | 270.93M | 265.12M | 323.62M | 358.81M | - | 413.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 96.16M | 100.53M | 100.04M | - | - | - | - | - | 47.16M | 89.91M | 74.91M | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B | 2.25B | 3.71B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 168.82M | 310.41M | 323.37M | 681.87M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 868.60M | 1.52B | 1.92B | 3.03B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.65B | 1.80B | 2.10B | 2.53B |
| Operating Income | -27.84M | -48.11M | -44.07M | -54.82M | -129.46M | -92.94M | -404.98M | -296.01M | -424.59M | -500.09M | -814.67M | -939.43M | -828.44M | -708.65M | -785.07M | -282.18M | -176.88M | 501.58M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -926.56M | -258.24M | -178.85M | 631.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 155.97M | 121.22M | 141.86M | 252.63M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.13B | -433.52M | -377.38M | 323.15M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.16M | 6.72M | -99.22M | 9.40M |
| Net Income | -26.25M | -47.59M | -43.52M | -57.65M | -106.01M | -89.22M | -360.39M | -290.07M | -410.11M | -490.87M | -761.50M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M | 313.75M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 | 2.33 |
| R&D Expense | 96.88M | 108.73M | 106.38M | 99.30M | 86.57M | 112.96M | 190.25M | 276.50M | 382.39M | 390.63M | 505.42M | 655.11M | 654.82M | 792.16M | 883.01M | 1.00B | 1.13B | 1.32B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 481.38M | 393.26M | 281.92M | 287.52M | 420.53M | 1.08B | 1.39B | 1.26B | 1.99B | 1.57B | 2.40B | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B | 4.97B |
| Total Equity | 199.17M | 202.12M | 177.97M | 158.23M | 118.00M | 134.05M | 270.35M | 936.27M | 1.26B | 920.22M | 1.77B | 1.30B | 1.44B | 1.02B | 588.20M | -158.22M | -220.64M | 67.09M | 789.18M |
| Cash & Equivalents | 105.16M | 191.79M | 137.47M | 74.60M | 70.23M | 51.41M | 53.17M | 75.18M | 180.90M | 193.62M | 645.36M | 420.15M | 547.18M | 496.58M | 819.98M | 866.39M | 812.69M | 966.43M | 1.66B |
| Total Liabilities | - | - | 303.42M | 235.03M | 163.92M | 153.47M | 150.18M | 143.33M | 121.80M | 342.59M | 228.30M | 272.84M | 956.44M | 2.39B | 3.06B | 3.70B | 4.05B | 4.17B | 4.18B |
| Current Liabilities | - | - | 110.73M | 102.05M | 80.99M | 48.34M | 53.86M | 95.33M | 62.10M | 131.70M | 144.25M | 179.49M | 352.59M | 585.27M | 695.71M | 767.91M | 967.79M | 1.19B | 1.47B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 65.49M | -72.14M | -84.34M | -87.07M | -115.61M | -68.66M | - | - | -307.70M | -382.79M | -562.62M | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M | -8.31M | 524.08M |
| Investing Cash Flow | 17.94M | 14.43M | 17.84M | 81.96M | 3.37M | -130.50M | - | - | 142.59M | -290.36M | 272.94M | -417.68M | -435.52M | -273.30M | 169.35M | -336.35M | -116.84M | 436.33M |
| Financing Cash Flow | 3.15M | 3.51M | 3.66M | 738.00K | 93.41M | 200.93M | - | - | 177.83M | 1.12B | 65.47M | 823.18M | 994.98M | 1.25B | 425.75M | 172.13M | 294.16M | -305.19M |
| Capital Expenditure | -10.76M | -4.95M | -4.73M | -1.29M | -8.35M | -4.01M | -8.96M | -12.95M | -64.56M | -104.21M | -126.89M | -140.16M | -70.36M | -76.37M | -72.06M | -62.21M | -34.28M | -58.70M |
| Free Cash Flow | 54.73M | -77.09M | -89.07M | -88.36M | -123.96M | -72.66M | - | - | -372.26M | -487.00M | -689.50M | -418.58M | -685.32M | -718.07M | -613.33M | 41.95M | -42.59M | 465.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.7% | 83.0% | 85.6% | 81.6% |
| Operating Margin % | -28.9% | -47.9% | -44.1% | - | - | - | - | - | -900.3% | -556.2% | -1,087.6% | -427.5% | -168.1% | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| Net Margin % | -27.3% | -47.3% | -43.5% | - | - | - | - | - | -869.6% | -545.9% | -1,016.6% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| ROE % | -13.0% | -26.7% | -27.5% | -48.9% | -79.1% | -33.0% | -38.5% | -22.9% | -44.6% | -27.8% | -58.5% | -61.6% | -84.5% | -145.0% | 714.9% | 199.5% | -414.6% | 39.8% |
| ROCE % | - | -13.0% | -15.1% | -27.3% | -54.1% | -25.3% | -41.1% | -22.4% | -37.5% | -27.0% | -58.4% | -46.0% | -29.4% | -24.0% | -28.3% | -9.9% | -5.8% | 14.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 11.23% | 15.02M | $3.60B |
| 2 | Capital World Investors | 8.33% | 11.14M | $2.67B |
| 3 | Blackrock Inc. | 8.15% | 10.91M | $2.61B |
| 4 | Capital Research Global Investors | 7.29% | 9.75M | $2.34B |
| 5 | Vanguard Portfolio Management LLC | 4.89% | 6.54M | $1.57B |
| 6 | Vanguard Capital Management LLC | 4.51% | 6.03M | $1.44B |
| 7 | T. Rowe Price Investment Management, Inc. | 4.22% | 5.64M | $1.35B |
| 8 | Invesco Ltd. | 2.81% | 3.75M | $899.38M |
| 9 | State Street Corporation | 2.66% | 3.56M | $851.80M |
| 10 | JPMORGAN CHASE & CO | 2.00% | 2.68M | $640.95M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALNY
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR TreatmentDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- "Hereditary Tra…
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass., September 02, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:…
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discus…
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
CAMBRIDGE, Mass., August 30, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-po…
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
ALNY — Frequently Asked Questions
What is the current share price of Alnylam Pharmaceuticals, Inc. (ALNY)?
As of 2026-09-19 21:16 PDT, Alnylam Pharmaceuticals, Inc. (ALNY) trades at $260.10 on NasdaqGS. Its 52-week range is $205.48 to $491.22.
What is the market capitalisation of ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalisation of $34.80B on NasdaqGS.
What is the P/E ratio of ALNY?
ALNY trades at a trailing price-to-earnings (P/E) ratio of 45.23. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 25.48.
What is the return on equity (ROE) of ALNY?
ALNY has a return on equity (ROE) of 96.56%. Its return on capital employed (ROCE) is 14.33%.
Is ALNY a good stock to buy?
This page provides a data-driven analysis of Alnylam Pharmaceuticals, Inc. (ALNY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.